echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Eur Respir J: COVID-19 Mediastinal Emphysema: A Manifestation of Severe COVID-19 Pneumonia?

    Eur Respir J: COVID-19 Mediastinal Emphysema: A Manifestation of Severe COVID-19 Pneumonia?

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background and purpose: Emphysema mediastinal (PTM) is the abnormal presence of air or gas in the mediastinum
    .


    Spontaneous PTM is rare, occurring in approximately 1 in 33,000 hospitalized patients


    Emphysema mediastinal (PTM) is the abnormal presence of air or gas in the mediastinal cavity


    RESULTS: During the study period, 377 cases of mediastinal emphysema were identified among 58,484 inpatients with COVID-19 in 53 hospitals, representing an incidence rate of 0.
    64%
    .


    The overall 120-day mortality rate for COVID-19 mediastinal emphysema was 195/377 (51.


    Table 1 Binary logistic regression model for predicting 120-day mortality from mediastinal air volume (all patients eligible for mechanical ventilation, n=315)
    .


    In univariate analysis, all variables significantly associated with mortality were entered stepwise backward into the model


    Table 1 Binary logistic regression model for predicting 120-day mortality from mediastinal air volume (all patients eligible for mechanical ventilation, n=315)


    Figure 1 Sankey Plot of maximal respiratory support for all patients 4 hours before and 4 hours after diagnosis of mediastinal emphysema (n = 374)
    .


    The mean fractions of inspired oxygen (FiO2) and positive end-expiratory pressure (PEEP) at these levels of support are shown in the table below


    Figure 1 Sankey Plot of maximal respiratory support for all patients 4 hours before and 4 hours after diagnosis of mediastinal emphysema (n = 374)


    Figure 2.
    Alluvial plot depicting the trajectories of 93 patients eligible for mechanical ventilation with continuous positive airway pressure (CPAP) at the time of diagnosis of mediastinal emphysema
    .


    At diagnosis, there were no statistically significant differences in age, maximal fractional inspiratory oxygen (FiO2), or maximal positive end-expiratory pressure (PEEP) in patients who subsequently continued CPAP versus those who subsequently switched to oxygen or high-flow nasal oxygen (HFNO) difference


    Figure 2.


    Figure 3 Mediastinal emphysema coexisting with subcutaneous emphysema, tension pneumothorax, and use of intercostal thoracic drainage tubes (n = 377)
    .


    Bilateral pneumothorax is caused by pneumothorax on both sides of the chest in the same patient

    Figure 3 Mediastinal emphysema coexisting with subcutaneous emphysema, tension pneumothorax, and use of intercostal thoracic drainage tubes (n = 377)


    Mediastinal emphysema may be a hallmark of severe COVID-19 pneumonia
    .
    Most patients with confirmed mediastinal emphysema are not on mechanical ventilation at the time of diagnosis
    .

    Original source: Melhorn J, Achaiah A, Conway FM, et al.
    Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the United Kingdom (POETIC) survey.
    Eur Respir J 2022 Feb 10

    Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the United Kingdom (POETIC) survey.
    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.